A method for preparing quinazolinone derivatives
By using the combination method of cuprous catalyst and bidentate ligand in the presence of copper catalyst and solvent, the preparation efficiency and selectivity of quinazolinone derivatives have been successfully improved, and the low efficiency of the preparation method in the prior art has been solved. Problem, high yield and high selectivity synthesis is achieved.
Patent Information
- Application Number
- CN202211577465.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-12-05
AI Technical Summary
In the prior art, there is a lack of high yield and high chemical selectivity preparation method for quinazolinone derivatives, and it is difficult to effectively prepare such important biologically active compounds.
In the presence of a copper catalyst and a solvent, compound 1, compound 2 and compound 3 are reacted, and the formation of carbon-nitrogen bonds is promoted through a cuprous catalyst, and separated under the action of a base. Binodent ligands are added to improve chemical selectivity. Reduce the reaction temperature and activation energy to avoid side reactions.
The high yield and chemical selectivity of quinazolinone derivatives are achieved, the simplicity and efficiency of synthesis are improved, and the generation of by-products is reduced.
Smart Images

Figure CN115850193B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for preparing quinazolinone derivatives. Background Art
[0002] Quinazolinone (4-quinazolinone, molecular formula C8H6N2O) is the skeleton structure of many alkaloids and drugs. It is a very important class of nitrogen-containing heterocyclic compounds. In recent years, people have conducted a lot of research on it, and gradually found that quinazoline and its various derivatives have very significant biological activity, which also makes this type of compound widely used in the fields of pesticides and medicine, such as sterilization, insecticide, antiviral, anti-inflammatory, anti-tumor, anti-hypertension, anti-tuberculosis, anti-malarial, etc. Relevant studies have confirmed that quinazoline and its various derivatives can inhibit the epidermal growth factor receptor (EGFR). EGFR itself has tyrosine kinase activity. Once combined with epidermal growth factor (EGF), it can activate related genes in the cell nucleus, thereby promoting cell division and proliferation. Therefore, EGFR has become a new target for tumor treatment. Therefore, quinazoline compounds play an important role in anti-tumor and anti-HIV. At the same time, quinazoline compounds are found to have strong lipophilicity, so they can significantly improve the drug resistance of cancer cells. Quinazoline compounds have good performance in preventing and treating cardiovascular diseases and can be used as receptor blockers to prevent atherosclerosis and coronary heart disease. In addition, quinazoline and its derivatives also have good antibacterial activity in pesticides.
[0003] There are still few reports on simple and direct methods for synthesizing quinazolinone derivatives. Therefore, it is necessary to provide a method for preparing quinazolinone derivatives with high yield and high chemical selectivity. Summary of the invention
[0004] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention provides a method for preparing quinazolinone derivatives, which can effectively improve the yield and chemical selectivity.
[0005] The method for preparing quinazolinone derivatives according to the first aspect of the present invention comprises the following steps:
[0006] In the presence of a copper catalyst and a solvent, compound 1, compound 2 and compound 3 are reacted to obtain a compound of formula (I);
[0007] Among them, the structural formulas of compound 1, compound 2, compound 3 and the compound of formula (I) are as follows:
[0008]
[0009] R1, R2, R3, R4, R5, R6, R7, R8 or R9 are independently selected from hydrogen, halogen, substituted or unsubstituted C 1~10 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted C 1~10 One of an alkoxy group, a substituted or unsubstituted amino group, a carboxyl group, an ester group, an acyl group, a cyano group, a nitro group, a hydroxyl group or an azide group;
[0010] X is selected from one of halogen, tetrafluoroboric acid, trifluoromethanesulfonic acid, hexafluorophosphate, p-toluenesulfonic acid, benzenesulfonic acid or methanesulfonic acid.
[0011] The method for preparing quinazolinone derivatives according to the embodiment of the present invention has at least the following beneficial effects:
[0012] The present invention selects compound 1, compound 2 and compound 3 to react in the presence of a cuprous catalyst to generate the compound of formula (I), which has the advantages of simple synthesis and high yield. This is because the cuprous catalyst is introduced into the compound by bonding to promote the formation of a carbon-nitrogen bond, and is separated under the action of a base to finally form a quinolinone compound.
[0013] According to some embodiments of the present invention, the preparation method further comprises adding a bidentate ligand that coordinates with the copper ions.
[0014] The role of adding ligands is to improve its chemical selectivity. This is because the introduction of ligands forms a coordination bond with the cuprous catalyst, which reduces the chemical potential of the reaction, further reduces the activation energy of the reaction, and thus reduces the reaction temperature of the three-component reaction (i.e., the reaction of substrates 1, 2, and 3). Thus, the occurrence of side reactions (which are prone to generate by-products quinazoline and acridone) is avoided.
[0015] According to some embodiments of the present invention, the bidentate ligand is selected from at least one of 1,2-diamine, 1,3-diamine, dicyclohexylphosphine or dibenzylideneacetone, and triphenylphosphine.
[0016] Cuprous catalysts can efficiently decompose diaryl iodine into phenyl cations and iodobenzene, thereby promoting the first step of cyanoaromatization reaction. And they can also act as Lewis acids to promote the second step of cyclization reaction.
[0017] According to some embodiments of the present invention, the copper catalyst is selected from at least one of cuprous iodide, cuprous chloride, cuprous bromide, and cuprous trifluoromethanesulfonate.
[0018] According to some embodiments of the present invention, the reaction temperature is 40°C to 150°C.
[0019] According to some embodiments of the present invention, the reaction temperature is 50° C. to 80° C. When the reaction temperature is selected to be 50° C. to 80° C., the yield is higher.
[0020] According to some embodiments of the present invention, the solvent is selected from at least one of dichloroethane, dichloromethane, chloroform, tetrahydrofuran, dioxane, benzene, toluene, trifluorotoluene, acetonitrile, ethyl acetate, ether, methyl tert-butyl ether, n-hexane, cyclohexane or petroleum ether.
[0021] According to some embodiments of the present invention, the molar ratio of Compound 1, Compound 2 and Compound 3 is 1:(1-1.5):(1-1.5).
[0022] According to some embodiments of the present invention, the reaction time is 1 h to 24 h.
[0023] According to some embodiments of the present invention, the solvent needs to be treated to be anhydrous and oxygen-free before use.
[0024] According to some embodiments of the present invention, after the reaction is completed, a purification step is further included.
[0025] According to some embodiments of the present invention, the purification step comprises post-treatment, concentration or column chromatography purification.
[0026] According to some embodiments of the present invention, the concentration is performed by evaporating the solvent to dryness by atmospheric distillation, reduced pressure distillation or rotary evaporation.
[0027] According to some embodiments of the present invention, the column chromatography uses 200-300 mesh silica gel as separation resin, and the eluent is selected from at least one of petroleum ether, dichloromethane, methanol, and ethyl acetate.
[0028] According to some embodiments of the present invention, some representative structural formulas of quinazolinone derivatives are shown below:
[0029]
[0030] Definitions and general terms
[0031] "Substituted or unsubstituted C 1-10 "alkyl" means an alkyl group having 1 to 10 carbon atoms, including C 1-10 Straight chain alkyl, C 1-10 The branched alkyl and C 3-10The cycloalkyl group may be, for example, a linear alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, a branched alkyl group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, or a cycloalkyl group having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, for example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, an n-hexyl group, a cyclopropyl group, a methylcyclopropyl group, an ethylcyclopropyl group, a cyclopentyl group, a methylcyclopentyl group, a cyclohexyl group, etc. Optionally, at least one H in the group is substituted by a corresponding group defined herein.
[0032] "Substituted or unsubstituted C 6~20 The term "aryl" refers to an all-carbon monocyclic or fused polycyclic group of 6 to 20 carbon atoms; having a completely conjugated π electron system. For example, benzene, naphthalene, indene, fluorene, etc. Optionally, at least one H in the group is substituted by a corresponding group defined herein.
[0033] "Substituted or unsubstituted C 1~10 "Alkoxy" means an alkoxy group having 1 to 10 carbon atoms, including C 1-10 Straight chain alkoxy, C 1-10 Branched alkoxy and C 2-10 The cycloalkoxy group may be, for example, a linear alkoxy group having a total number of carbon atoms of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, a branched alkoxy group having a total number of carbon atoms of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, or a cycloalkoxy group having a total number of carbon atoms of 2, 3, 4, 5, 6, 7, 8, 9 or 10, for example, a methoxy group, an ethoxy group, a n-propoxy group, an isopropoxy group, etc. Optionally, at least one H in the group is substituted by a corresponding group defined herein.
[0034] "Substituted or unsubstituted amino" means that at least one H in the group is substituted by a corresponding group as defined herein.
[0035] “C 2~10 The ester group of The ester group, wherein C 2~10 The ester group refers to an ester group having a total of 2 to 10 carbon atoms, and representative examples include methyl formate, ethyl formate, ethyl acetate, methyl acetate, and the like.
[0036] Other features and advantages of the present invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0038] Figure 1 The compound (I-a) prepared in Example 1 1 H NMR spectrum;
[0039] Figure 2 The compound (I-b) prepared in Example 2 1 H NMR spectrum;
[0040] Figure 3 The compound (I-c) prepared in Example 3 1 H NMR spectrum;
[0041] Figure 4 The compound (I-d) prepared in Example 4 1 H NMR spectrum;
[0042] Figure 5 The compound (I-e) prepared in Example 5 1 H NMR spectrum;
[0043] Figure 6 The compound (I-f) prepared in Example 6 1 H NMR spectrum;
[0044] Figure 7 The compound (I-g) prepared in Example 7 1 H NMR spectrum;
[0045] Figure 8 The compound (I-h) prepared in Example 8 1 H NMR spectrum;
[0046] Fig. 9 This is the HPLC spectrum of the reaction solution of the compound (I-a) prepared in Example 1 without purification. DETAILED DESCRIPTION
[0047] The following are specific embodiments of the present invention, and the technical solutions of the present invention are further described in conjunction with the embodiments, but the present invention is not limited to these embodiments.
[0048] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0049] Example 1
[0050] Example 1 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0051]
[0052] Method 1: Weigh trifluoromethanesulfonic acid di-o-anisyl iodonium salt (1mmol, 461mg), cuprous iodide (0.1mmol, 19mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add chloroacetonitrile (1mmol, 75.5uL), methyl 2-amino-6-methylbenzoate (1mmol, 141.4uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into a 65℃ oil bath and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether:ethyl acetate = 8:1 as eluent to obtain pure 2-chloromethyl-3-methoxyphenyl-5-methylquinazolinone as a yellow solid with an isolation yield of 71%.
[0053] Method 2: Weigh trifluoromethanesulfonic acid di-o-anisyl iodonium salt (1mmol, 461mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add chloroacetonitrile (1mmol, 75.5uL), methyl 2-amino-6-methylbenzoate (1mmol, 141.4uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into a 130℃ oil bath and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether:ethyl acetate = 8:1 as eluent to obtain pure 2-chloromethyl-3-methoxyphenyl-5-methylquinazolinone as a yellow solid with an isolation yield of 87%.
[0054] Structural identification of structural formula (Ia):
[0055] NMR data:
[0056] 1 H NMR(400MHz,Chloroform-d)δ7.68–7.57(m,2H),7.54–7.46(m,1H),7.36–7.26(m,2H),7.20–7. 04(m,2H),4.31(dd,J=11.9,1.1Hz,1H),4.11(dd,J=11.9,1.1Hz,1H),3.80(s,3H),2.84(s,3H);
[0057] ESI-HRMS: m / z calcd for C 17 H 15 ClN2O2[M+H] + :314.7690, found 314.7691.
[0058] (Ia) Compound 1 H NMR spectrum Figure 1 As shown, the analysis results show that the target product obtained is correct.
[0059] Fig. 9 HPLC spectrum of the unpurified reaction solution of compound (I-a) prepared by method 2 of Example 1. From the spectrum, it can be analyzed that the reaction has high chemical selectivity.
[0060] Embodiments 2 to 5
[0061] Examples 2 to 5 provide a series of methods for preparing quinazolinone derivatives. The preparation method is basically the same as that of Example 1, except that the cuprous catalyst is different. The specific results are shown in Table 1.
[0062] Table 1
[0063] Copper Catalyst Yield % Example 2 Cuprous iodide 87 Example 3 Cuprous chloride 82 Example 4 Cuprous Bromide 85 Example 5 Cuprous trifluoromethanesulfonate 93
[0064] Embodiments 6 to 10
[0065] Examples 6 to 10 provide a series of preparation methods for quinazolinone derivatives. The preparation method is basically the same as that of Example 1, except that the ligands are different. The specific results are shown in Table 2.
[0066] Table 2
[0067] Bidentate ligand Yield % Example 6 1,2-Diamine 31 Example 7 1,3-Diamine 39 Example 8 Biscyclohexylphosphine 68 Example 9 Dibenzylideneacetone 91 Example 10 Triphenylphosphine 82
[0068] Examples 11 to 15
[0069] Examples 11 to 15 provide a series of preparation methods for quinazolinone derivatives. The preparation method is basically the same as Example 1, except that the reaction temperature is different. The specific results are shown in Table 3.
[0070] Table 3
[0071] Reaction temperature / ℃ Yield % Embodiment 11 40 20 Example 12 50 49 Embodiment 13 80 86 Embodiment 14 130 82 Embodiment 15 150 79
[0072] Example 16
[0073] Example 16 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0074]
[0075] Weigh trifluoromethanesulfonic acid di-o-tolyl iodonium salt (1mmol, 458mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add chloroacetonitrile (1mmol, 75.5uL), methyl 2-amino-6-methylbenzoate (1mmol, 141.4uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into a 65℃ oil bath and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether: ethyl acetate = 8:1 as eluent to obtain pure 2-chloromethyl-5-methyl-o-tolylquinazolinone as a yellow solid with an isolation yield of 95%.
[0076] NMR data:
[0077] 1 H NMR(400MHz,Chloroform-d)δ7.63(d,J=2.1Hz,2H),7.41(dd,J=6.5,2.6Hz,3H),7. 27(s,2H),4.34–4.23(m,1H),4.14–4.07(m,1H),2.83(d,J=8.1Hz,3H),2.17(s,3H);
[0078] ESI-HRMS:m / z calcd for C17H15ClN2O[M+H]+:298.7700, found 298.7701.
[0079] The 1H NMR spectrum of the compound of formula (Ia) is as follows Figure 2 As shown: The analysis results show that the target product obtained is correct.
[0080] Embodiment 17
[0081] Example 17 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0082]
[0083] Weigh diphenyliodonium trifluoromethanesulfonate (1mmol, 429mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add chloroacetonitrile (1mmol, 75.5μL), methyl 2-amino-6-methylbenzoate (1mmol, 141.4uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into an oil bath at 130℃ and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether:ethyl acetate = 8:1 as eluent to obtain pure 2-chloromethyl-5-methyl-3-phenylquinazolinone as a yellow solid with an isolation yield of 85%.
[0084] NMR data:
[0085] 1 H NMR (400MHz, DMSO-d6) δ7.73(t,J=7.8Hz,1H),7.66–7.52(m,4H),7.52–7.41(m,2H),7.37(d,J=7.4Hz,1H),4.29(s,2H),2.73(s,3H);
[0086] ESI-HRMS: m / z calcd for C 16 H 13 ClN2O[M+H] + :284.7430,found 284.7431.
[0087] The compound of formula (Ic) 1 H NMR spectrum Figure 3 As shown: The analysis results show that the target product obtained is correct.
[0088] Embodiment 18
[0089] Example 18 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0090]
[0091] Weigh trifluoromethanesulfonic acid di-o-anisole iodonium salt (1mmol, 461mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add bromoacetonitrile (1mmol, 119.9μL), 2-amino-6-chlorobenzoic acid methyl ester (1mmol, 158.9uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into a 130℃ oil bath and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether:ethyl acetate = 8:1 as eluent to obtain pure 2-bromomethyl-5-chloro-3-methoxyphenylquinazolinone as a yellow solid with an isolation yield of 82%.
[0092] NMR data:
[0093] 1 H NMR(400MHz,Chloroform-d)δ7.70–7.62(m,2H),7.50(td,J=8.5,8.0,1.7Hz,2H),7.33(dd,J=7 .8,1.7Hz,1H),7.16–7.05(m,2H),4.29(d,J=12.0Hz,1H),4.10(d,J=12.0Hz,1H),3.79(s,3H);
[0094] ESI-HRMS: m / z calcd for C 16 H 12 BrClN2O2[M+H] + :379.6380, found 379.6381.
[0095] The compound of formula (Id) 1 H NMR spectra, such as Figure 4 As shown: The analysis results show that the target product obtained is correct.
[0096] Embodiment 19
[0097] Example 19 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0098]
[0099] Weigh trifluoromethanesulfonic acid di-o-tolyl iodonium salt (1mmol, 458mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add bromoacetonitrile (1mmol, 119.9uL), 2-amino-6-chlorobenzoic acid methyl ester (1mmol, 158.9uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into a 130℃ oil bath and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether: ethyl acetate = 8:1 as eluent to obtain pure 2-bromomethyl-5-chloro-o-tolylquinazolinone as a yellow solid with an isolation yield of 86%.
[0100] NMR data:
[0101] 1 H NMR(400MHz,Chloroform-d)δ7.68(d,J=7.8Hz,2H),7.54(dd,J=7.3,1.9Hz,1H),7.48 –7.31(m,3H),7.25(dd,J=9.1,2.2Hz,1H),4.19(dd,J=62.9,11.9Hz,2H),2.18(s,3H);
[0102] ESI-HRMS: m / z calcd for C 16 H 12 BrClN2O[M+H] + :363.6390, found 363.6391.
[0103] The compound of formula (Ie) 1 H NMR spectrum Figure 5 As shown, the analysis results show that the target product obtained is correct.
[0104] Embodiment 20
[0105] Example 20 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0106]
[0107] Weigh diphenyliodonium trifluoromethanesulfonate (1mmol, 429mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add chloroacetonitrile (1mmol, 75.5uL), methyl anthranilate (1mmol, 130.3uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into an oil bath at 130℃ and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether:ethyl acetate = 8:1 as eluent to obtain pure 2-chloromethyl-3-phenylquinazolinone as a yellow solid with an isolation yield of 78%.
[0108] NMR data:
[0109] 1 H NMR (400MHz, Chloroform-d) δ8.33–8.27(m,1H),7.81(t,J=8.9Hz,2H),7.60–7.52(m,4H),7.51–7.22(m,3H),4.27(d,J=1.6Hz,2H);
[0110] ESI-HRMS: m / z calcd for C 15 H 11 ClN2O[M+H] + :270.7160,found 270.7161.
[0111] Formula (If) 1 H NMR spectrum Figure 6 As shown, the analysis results show that the target product obtained is correct.
[0112] Embodiment 21
[0113] Example 21 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0114]
[0115] Weigh diphenyliodonium trifluoromethanesulfonate (1mmol, 429mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add 2-azidoacetonitrile (1mmol, 82uL), methyl 2-amino-6-chlorobenzoate (1mmol, 158.9uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into an oil bath at 130℃ and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by a rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether:ethyl acetate = 8:1 as eluent to obtain pure 2-azidomethyl-5-chloro-3-phenylquinazolinone as a yellow solid with an isolation yield of 76%.
[0116] NMR data:
[0117] 1 H NMR (400MHz, Chloroform-d) δ8.02(s,1H),7.67(d,J=5.1Hz,2H),7.45–7.40(m,3H),7.28(s,1H),7.20(d,J=6.9Hz,1H),3.93(d,J=27.9Hz,2H).
[0118] ESI-HRMS: m / z calcd for C 15 H 10 ClN5O[M+H] + :311.7290, found 311.7291.
[0119] Formula (Ig) 1 H NMR spectrum Figure 7 As shown, the analysis results show that the target product obtained is correct.
[0120] Embodiment 22
[0121] Example 22 provides a method for preparing a quinazolinone derivative, the structural formula and preparation method of which are as follows:
[0122]
[0123] Weigh trifluoromethanesulfonic acid di-o-tolyl iodonium salt (1mmol, 458mg), cuprous iodide (0.1mmol, 19mg), dibenzylideneacetone (0.1mmol, 24mg) in a 25mL sealed tube, add a magnetic particle, replace with high-purity nitrogen three times, add chloroacetonitrile (1mmol, 75.5uL), 2-amino-6-fluorobenzoic acid methyl ester (1mmol, 144.7uL), 3mL dichloroethane to the sealed tube under nitrogen protection, tighten the sealed tube, move it into a 130℃ oil bath and stir, react overnight. Use TLC to track the reaction. After the reaction is completed, cool the sealed tube to room temperature. Add 5mL of distilled water to the system and stir; extract with ether (5mL×3). The organic phases were combined and the solvent was removed by rotary evaporator to obtain a crude product; the crude product was supported on silica gel and purified by column chromatography using a volume ratio of petroleum ether:ethyl acetate = 8:1 as eluent to obtain a pure compound of formula (Ih) as a yellow solid with an isolation yield of 72%.
[0124] NMR data:
[0125] 1 H NMR (400MHz, DMSO-d6) δ7.93–7.86(m,1H),7.61(d,J=8.2Hz,1H),7.45(s,3H),7.39(d,J=9.1Hz,2H),4.26(s,2H),2.08(s,3H).
[0126] ESI-HRMS: m / z calcd for C 16 H 12 ClFN2O[M+H] + :302.7334, found 302.7335.
[0127] The compound of formula (Ih) 1 H NMR spectrum Figure 8 As shown, the analysis results show that the target product obtained is correct.
[0128] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge scope of ordinary technicians in the relevant technical field without departing from the purpose of the present invention.
Claims
1. A method for preparing a quinazolinone derivative, It is characterized in that The steps include: In the presence of a cuprous catalyst, a bidentate ligand and a solvent, compound 1, compound 2 and compound 3 are reacted to obtain a compound of formula (I); Among them, the structural formulas of compound 1, compound 2, compound 3 and the compound of formula (I) are as follows: ; R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 or R 9 are independently selected from hydrogen, halogen, C 1~10 Alkyl, C 6~20 Aryl or C 1~10 One of the alkoxy groups; R 5 is selected from halogen or azide; X is selected from one of halogen, tetrafluoroboric acid, trifluoromethanesulfonic acid, hexafluorophosphate, p-toluenesulfonic acid, benzenesulfonic acid or methanesulfonic acid; The bidentate ligand is selected from at least one of dicyclohexylphosphine, dibenzylideneacetone or triphenylphosphine; The cuprous catalyst is selected from at least one of cuprous iodide, cuprous chloride, cuprous bromide or cuprous trifluoromethanesulfonate.
2. The preparation method according to claim 1, It is characterized in that The reaction temperature is 40°C to 150°C.
3. The preparation method according to claim 2, It is characterized in that The reaction temperature is 50°C to 80°C.
4. The preparation method according to claim 1, It is characterized in that The solvent is selected from at least one of dichloroethane, dichloromethane, chloroform, tetrahydrofuran, dioxane, benzene, toluene, trifluorotoluene, acetonitrile, ethyl acetate, ether, methyl tert-butyl ether, n-hexane, cyclohexane or petroleum ether.
5. The preparation method according to claim 1, It is characterized in that The molar ratio of compound 1, compound 2 and compound 3 is 1:(1-1.5):(1-1.5).
6. The preparation method according to claim 1, It is characterized in that The reaction time is 1 h to 24 h.
7. The preparation method according to claim 1, It is characterized in that After the reaction is completed, a purification step is also included.
